BRIEF—CSL Behring presents positive data for hereditary angioedema therapy

Australia’s CSL Behring has presented positive data on hereditary angioedema (HAE) therapy Haegarda (C1 esterase inhibitor).

The data show Haegarda reduced the median number of HAE attacks per month by 98% in subjects who had frequent attacks, from a 16-week placebo period to a 16-week treatment period.

The presented subgroup analysis was based on data from the Phase III COMPACT trial.

The therapy is approved in the USA for routine prophylaxis to prevent HAE attacks in adolescent and adult patients.